Neoadjuvant Clinical Trials

6 recruiting

Neoadjuvant Trials at a Glance

111 actively recruiting trials for neoadjuvant are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 53 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Wuhan. Lead sponsors running neoadjuvant studies include Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, and Tongji Hospital.

Browse neoadjuvant trials by phase

Treatments under study

About Neoadjuvant Clinical Trials

Looking for clinical trials for Neoadjuvant? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoadjuvant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoadjuvant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 111 trials

Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Not Applicable

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

Neoadjuvant Therapy
Fudan University66 enrolled1 locationNCT07541664
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Phase 2

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerNeoadjuvant TherapyInvasive Breast Carcinoma+2 more
Atlas University80 enrolled1 locationNCT07289282
Recruiting
Phase 2

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)

Neoadjuvant TherapyNSCLC
Qian Chu500 enrolled2 locationsNCT07388771
Recruiting
Phase 3

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell CarcinomaNeoadjuvant
ZHOU FANGJIAN298 enrolled8 locationsNCT05738694
Recruiting
Not Applicable

Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer

Breast Cancer (Locally Advanced or Metastatic)Neoadjuvant ChemoimmunotherapyTattoo Skin Markers
All India Institute of Medical Sciences, Bhubaneswar30 enrolled1 locationNCT07478900
Recruiting
Phase 2

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Locally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v8+26 more
Roswell Park Cancer Institute45 enrolled1 locationNCT04511039
Recruiting

Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer

Neoadjuvant TherapyColorectal Carcinoma (CRC)Complications+1 more
Osijek University Hospital68 enrolled1 locationNCT07422974
Recruiting
Phase 1Phase 2

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Esophageal Squamous Cell CarcinomaNeoadjuvantIvonescimab
Tang-Du Hospital45 enrolled1 locationNCT07385001
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Neoadjuvant TherapyClear Cell Renal Cell CarcinomaIparomlimab and Tuvonralimab
Sun Yat-sen University25 enrolled1 locationNCT07389629
Recruiting
Not Applicable

Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study

Breast CancerProstate CancerNeoadjuvant Therapy+2 more
Mälardalen University172 enrolled2 locationsNCT06719206